

Abnormalities of Vascular System

Chapter 2

Ameliorative Potential of Curcumin Phytosome in Streptozotocin induced Vascular Dementia in *Danio rerio*

Arunachalam Muthuraman*; Narahari Rishitha

Department of Pharmacology, JSS College of Pharmacy, Jagadguru Sri Shivarathreeshwara University, Mysuru-570 015, Karnataka, India

*Correspondence to: Arunachalam Muthuraman, Department of Pharmacology, JSS College of Pharmacy, Jagadguru Sri Shivarathreeshwara University, Mysuru-570 015, Karnataka, India

Tel.: +91-9988040886; E-Mail: arunachalammu@gmail.com

Abstract

Curcumin is major principal curcuminoid found in turmeric and in various medicinal plants. It has numerous numbers of pharmacological actions like anti-oxidant, cell cycle regulation; ions channel modulators and vascular integrity. The present study is designed for the evaluation of curcumin phytosome (CP) in streptozotocin induced vascular dementia (VaD) in *Danio rerio*. The vascular dementia was induced by intraperitoneal injection of streptozotocin (STZ; 350 mg/kg). The pre-treatment of curcumin CP (20 and 40 mg/kg; *i.p.*) was administered for 28 consecutive days. The reference control *i.e.*, insulin (10 mM/kg) and donepezil (10 mg/kg) was also administered for 28 consecutive days. The sign of VaD *i.e.*, learning and memory levels were evaluated with different behavioural tests like light & dark chamber test; partition preference test; three (horizontal) compartment tests; and T-maze test. In addition, the STZ induced biochemical changes such as glucose & homocysteine levels in plasma; and acetylcholinesterase activity, lipid peroxidation & reduced glutathione levels in brain samples of zebrafish were assessed. The CP found to possess the attenuating effect in STZ induced VaD along with alterations of biochemical changes. This effect is similar to that of reference control *i.e.*, donepezil pre-treated group. Therefore, this CP can be used as future natural medicine for various neurovascular disorders like VaD due to its potential anti-hyperglycemic, reduction of homocysteine, anti-lipid peroxidative, anti-oxidative and acetylcholinesterase inhibitory actions.

Keywords: Curcumin phytosome; *Danio rerio*; Homocysteine; Streptozotocin; Vascular Dementia

Abbreviations

AChE: Acetylcholinesterase; AD: Alzheimer's disease; BBB: Blood brain barrier; CP: Curcumin phytosome; DTNB: 5,5'-Dithiobis-(2-Nitrobenzoic Acid); ETC: Entry to the target chamber; GSH: Reduced glutathione; HcY: Homocysteine; HPLC: High-performance liquid chromatography i.p. Intraperitoneal; NEDC: Number of entry to the dark chamber; ODS: Octa decyl silane; SDS: Sodium dodecyl sulphate; STZ: Streptozotocin; TBARS: Thiobarbituric acid reactive substances; TL: Transfer latency; TPSA: Target preference of short arm; TSLC: Time spent in the light chamber; TSLS: Time spent in lower segment; TSTC: Time spent in the target chamber; TSUS: Time spent in upper segment; VaD: Vascular dementia

1. Introduction

The impairment of cerebral blood flow is one of the primary pathophysiological events for the development of vascular dementia (VaD). It can be defined as “the declining of thinking ability and skills due to blockage and/or reduction of cerebral blood flow (global or regional) to the brain viz deprivation of brain cellular oxygen and nutrients supply. The primary symptoms are lack of reasoning, planning, judgment, memory and other thoughtful processes. The global incidence of VaD is higher than prevalence rate. Worldwide it is estimated around 6 to 12 cases per every 1000 population and it occurs in above the 70 years of age. The average duration of VaD is around 5 years and survival rate is lower than Alzheimer's disease (AD). In India, VaD is preventable with some extent of therapy [1]. However, the availability of literature is limited.

Learning is a process of acquisition and any new information obtained from surroundings and registered in brain especially in hippocampus; whereas, the retrieving of this information i.e., recalling of stored information is referred as memory [2]. In addition, the VaD associated memory impairment comprises the lack of registration, consolidation and retrieval process of information by brain tissue and in this condition known as cognitive dysfunction [3,4]. The various non-rodent animal models such as *Drosophila melanogaster* (fruit fly) and *Caenorhabditis elegans* are employed for the screening of nootropic drugs [5]. Currently, zebrafish (*Danio rerio*) is also employed in the assessment of neurovascular dysfunction associated dementia [6]. Further, this model is well accepted for the drug discovery process due to closely mimicking function human genome as well as neurophysiology actions [7,8]. Neurological system is one of the high energy utilizing tissue; and lack of nutrients and blood flow are leads to produce the VaD [9,10]. Streptozotocin (STZ) is potent toxicant for beta cells of pancreatic gland viz raise the diabetic complication leads to VaD [11,12]. In addition, it's also modulates the metabolic alteration and reduction of neurotransmitters levels leads to accumulation of homocysteine and reduction acetylcholine level respectively [13,14].

Currently, the AD medications are recommended for the treatment of VaD like donepezil [Aricept®: acetylcholinesterase (AChE) inhibitor]; galantamine (Reminyl®: partial AChE

inhibitor, positive allosteric modulator of nicotinic acetylcholine receptors and inhibitor of beta-amyloid aggregation); and rivastigmine (Exelon[®]: dual inhibitor of acetylcholinesterase and butyrylcholinesterase). Paradoxically, the long term usage of these conventional nootropic agents is also documented to produce the various unwanted serious side effects. Hence, the newer drug discovery is essential for the neurovascular disorders like vascular dementia. Therefore, the present study designed to evaluate the role of curcumin phytosome (CP) in STZ induced vascular dementia in *Danio rerio*.

2. Materials and Methods

2.1. Animals

Wild type adult (< 8 month old male) zebrafish was used in this study. Animal kept in 10 liter (potable water) housing tank. Further, the tank was maintained with aerator for aeration (for making oxygen enriched environment) process; the temperature *i.e.*, 25 ± 2 °C was maintained with aquarium temperature; and 11 to 12 light and dark cycle of photoperiod for maintain the normal circadian rhythmicity. The home cage tank was closed with rubber board to avoid diving outside of the tank and damage of the tissue. All the animals were acclimatized for 2 weeks before the performance of behavioural assessment. All behavioural observation was performed between the 09.00 AM to 01.00 PM to avoid the hormone associated neurobiological interaction and neurobehavioral abnormalities.

2.2. Drugs and chemicals

Trichloro acetic acid, 5,5-dithiobis(2-nitrobenzoic acid), reduced glutathione, thiobarbituric acid, 1,1,3,3-Tetra methoxy propane, acetylthiocholine iodide and streptozotocin (STZ) were purchased from Sigma chemical, India. Curcumin phytosome (CP) was procured from Jarrow formulas, Los angeles, California, USA. CP dissolved in distilled water. The reference control drug *i.e.*, donepezil was procured from Intas pharmaceutical Ltd, India.

2.3. Induction of vascular dementia (VaD)

The diabetes was induced by intraperitoneal injection of STZ to zebrafish as described method of Intine [15]; and Sarras and Kinkel [16]. Briefly, 350 mg/kg of STZ was injected in zebrafish under anaesthetic condition (ice cold solution). Stock solution was prepared by mixing of 7 mg of STZ in 1ml of normal saline (0.9 % w/v sodium chloride). One gram of zebrafish was injected (*i.p.*) with 50 microliter of stock solution by using insulin syringe (27 ½ gauge needle). After 24 hours, blood glucose was estimated by using glucometer (drop of blood was obtained by applications of lancet needle side of the back fins). The diabetic conditions of zebrafish were considered when stable blood glucose level raised above 15mM of glucose.

2.4. Experimental protocol

Five groups of adult male zebrafish ($n = 20$), were employed in the present study. Group I: Normal control group; Group II: STZ (350 mg/kg; *i.p.*) treated group; Group III and IV: STZ + curcumin phytosome (CP; 20 and 40 mg/kg; *i.p.* for 28 consecutive days) treated group; Group V: STZ + Insulin (100 mM, *i.p.* for 28 consecutive days) treated group; Group VI: STZ + Donepezil (10 mg/kg; *i.p.* for 28 consecutive days) treated group. Thereafter, the behavioural parameters were assessed on 28th day; whereas, T maze training made on 28th day and assessment of vascular dementia made on day 29. On 29th day, all the animals were sacrificed and blood samples were collected for the glucose and homocysteine estimation.

2.5. Assessment of neurocognitive functions

The cognitive functions are evaluated with different tests like light & dark chamber test; partition preference test; three (horizontal) compartment tests; and T-maze Test. Zebrafish was engaged for the evaluation of neurocognitive functions with different test apparatus after exposing of STZ. All animals were acclimatized for 5 minutes in all behavioural test apparatus to minimize the error report.

2.5.1. Light and dark chamber test

Light and dark chamber test is one of the methods of spatial memory function as described by Dubey *et al.* [17]. Briefly, the dimension of this apparatus is 20 cm length, 10 cm width and 23 cm height. The water level was maintained up to the level of 12 cm and it is divided into the two equal (10 cm) vertical segments. One half is covered with black paper and it is considered as dark chamber. Another half is allow passing the natural light (50 Lux). The cognitive function was evaluated by assessment “*Time spent in the light chamber*” termed as TSLC and “*Number of entry to the dark chamber*” termed as NEDC. Generally, when animal placed in the new chamber it prefers the darker side for few seconds (it may be due to fearful about newer environment); within few seconds it will move towards the light chamber. If animal not move to the light chamber it has poor memory. If animal preferred light chamber indicates that memory function improved.

2.5.2. Partition preference test

Partition preference test is another method for the assessment of working and spatial memory function as described by Dubey *et al.* [17]. Briefly, the dimension of this apparatus is 20 cm length; 10 cm width; and 23 cm height. The water level was maintained up to the 3 cm. And, it is divided in to two equal (10 cm) vertical segments with glass (slide movement) and gap was maintained for 1 cm from ground level of the tank. The cognitive function was evaluated by assessment of number of entry to the target chamber and calculated as “*Time spent*

in the target chamber” (TSTC); and another one is named as “*Percentage entry to the target chamber*” (% ETC). Generally, when animal placed in the home chamber; it prefers to go target chamber. If animal not enter to home chamber within 60 seconds; animal was keeping in target chamber by blocking of way with glass slid. Thereafter, the way was open for further 60 seconds for home chamber entry. The preference of both chambers indicates the enhanced memory function. The preference of home chamber is the lack of memory function.

2.5.3. Three horizontal compartment test

Three horizontal compartment test is another method for the assessment of neurocognitive function as described by Dubey *et al.* [17]. Briefly, training section one day before fish were placed in the test chamber and guided to swim in all segments. This is achieved by side way movement of red colour (like / dislike) object. This training period was allowed for 60 seconds. Generally animal prefer in the bottom segment for few seconds (due to fearful newer environment). If animal not move in the upper two segments can be train by application of food pellet on the top of the surface or show the external object in different segment. It is required only few seconds. Thereafter, animals are ready to swim in all segments with normal swimming speed. This training will be successful if using single animal species. Paradoxically, if more than one animal species placed; the segment preference varies based on other animal movement. In addition, the other factors like age, gender and races of the animal are also make the variable of segment swimming. The cognitive function was evaluated by assessment of “*time spent in upper segment*” (TSUS); and “*time spent in lower segment*” (TSLS). Generally, when animal placed in the test chamber; it prefers to swim in upper segment of chamber within 15 seconds. It indicates that, the animal has normal or improved memory function. If animal not prefer the upper segment (even guided with likable stick or food); and animal swim in middle or lower segment indicates that loss of memory. The present study employed the individual assessment in trial as well as in test to achieve accurate results.

2.5.4. T-maze test

T-maze test is another method for the assessment of neurocognitive function. The T-maze test is one of the conventional methods of memory assessment in rodent species. T-maze test was performed as described method of Buccafusco *et al.* and Colwill *et al.* [18,19]. Briefly, T maze apparatus consist of two short arms (10 cm length; 6 cm width; and 10 cm height) with different colour (one arm with red colour glass; and another end arm coloured with green colour). And one long arm (20 cm length; 10 cm width; and 10 cm height). One short arm (green colour arm) employed as favourable environment with reward of food pellet (if preferred) and another short arm (red colour) employed as punishment by string with glass rod. One day before test assessment; all animal were allowed learn the T maze environment and trained for the learning process. Next day, animals were placed in the corner of long arm

(starting point) and target point was identified for either any one of the short arm. The starting point and target point were separated by vertical slide control pattern. Each fish was explored for 2 minutes for the learning and memory assessment. The transfer latency (TL) and percentage target (green) preference of short arm (% TPSA) were noted for the assessment of cognitive function. The animal movements were tracked by USB camera with computer software (12 Megapixel USB Camera, Intex, India).

2.6. Estimations of biomarker changes in blood

2.6.1. Blood sample collection

The blood samples were collected at the end of the study protocol from zebrafish as described method of Pedroso *et al.* and Babaei *et al.* [20,21]. Briefly, fish were placed on the petri dish and with steel blade the diagonal incision made between the anal fin and the caudal fin and placed in centrifugal tube. The centrifuge tube was prefilled with 100 μ l of anticoagulant (11 % w/v of sodium citrate). This setup was allowed to centrifuge at 1000 rpm for 10 minutes. Then, zebrafish removed from the centrifuge tube and blood samples were centrifuged with 2500 rpm for 15 minutes to collect the plasma for the estimations of glucose and homocysteine levels. The dilution was made with 1 : 4 ratio with anti-coagulant solution.

2.6.2. Estimation of plasma glucose

The plasma samples were used for the assessment of glucose estimation as described method *i.e.*, glucose oxidase and glucose peroxidase (GOD–POD) reactions Ambade *et al.* [22]. Streptozotocin treated zebrafish raise the blood glucose levels Intine *et al.* [15]. The GOD–POD reaction associated colour development with glucose levels were estimated by spectrophotometric method (DU 640B Spectrophotometer, Beckman Coulter Inc., 263 CA, USA) at 505 nm. The glucose estimation kit was commercially available in market (Reckon Diagnostics Pvt. Ltd. Vadodara, India).

2.6.3. Estimation of homocysteine level

The plasma samples were used for the assessment of homocysteine estimation by HPLC method as described by Radha Rama Devi *et al.* [23]. Briefly, reverse-phase HPLC with fluorescence detection was used for plasma homocysteine estimation. The 50 μ L plasma was mixed with 50 μ l of 0.8 M perchloric acid and vortexed vigorously. Then centrifugation was made at $1700 \times g$ for 10 min. The 50 μ L of supernatant was mixed with 20 ml of SBDF (ammonium 7-fluorobenzo-2-oxa-1, 3-diazole-4sulphonate; 1 mg/ml in 125 mM boric acid) was added and incubated at 60 °C for one hour. Then samples were injected in HPLC column with mobile phase at a flow rate of 1.5 ml per min. The column equilibration time was maintained for 15 minutes with ambient temperature. The retention time of each sample was calculated by using

homocysteine standard plot with the help of calibration curve (made with different concentrations). Stationary phase *i.e.*, octadecylsilane (ODS) 250 X 4.6 mm column; and mobile phase *i.e.*, 4 % acetonitrile in potassium dihydrogen orthophosphate (0.2 M, p^H : 2.1) was used in this study. The excitatory and emission light beam source were detected with fluorescent detector at 385nm and 515 nm wavelength respectively.

2.7. Estimations of biomarker changes in brain

2.7.1. Brain sample collection

After assessment of behavioural assessment and blood sample collection; the zebrafish brain samples were isolated immediately by microsurgical method and freeze dried at $-4^{\circ}C$. Next day, all samples were homogenate with phosphate buffer solution. The supernatant were collected by centrifugation at 1372 g force for 15 minutes. The supernatant of zebrafish brain samples were used for estimation of tissue biomarker changes *i.e.*, thiobarbituric acid reactive substances (TBARS), reduced glutathione (GSH) and acetylcholine esterase (AChE) activity levels.

2.7.2. Estimation of TBARS level in zebrafish brain

The TBARS level of zebrafish brain samples were estimated by spectroscopic method as described by Ohkawa *et al.* [24]. Briefly, 0.2 ml of tissue supernatant was mixed with 0.2 ml of 8.1 % w/v of sodium dodecyl sulphate (SDS), 1.5 ml of 30 % v/v of acetic acid (p^H 3.5), 1.5 ml of 0.8 % w/v of thiobarbituric acid and volume made up to 4 ml with distilled water. All the test tubes were incubated at $95^{\circ}C$ for 1 hour. Then cooled with tap water and further added 1 ml of distilled water and 5 ml of n-butanol-pyridine (15:1 v/v) mixture. After 10 minutes, tubes were centrifuged at 1372 g force for 15 min. The clear pink colour chromogen of supernatant was collected. The formation of pink colour and their intensity is based on the presence of TBARS content in tissue sample. The change of absorbance was noted by spectrophotometrically (DU 640B Spectrophotometer, Beckman Coulter Inc., CA, USA) at 535 nm wavelength. These readings were used for the further calculation of TBARS levels in tissue samples. The results were expressed as nM per mg of protein.

2.7.3. Estimation of GSH level in zebrafish brain

The GSH level of zebrafish brain samples were estimated by spectroscopic method as described by Ellman [25]. Briefly, 0.5 ml supernatant was mixed with 2 ml of 0.3 M of disodium hydrogen phosphate solution and 0.25 ml of 0.001 M of freshly prepared DTNB solution to develop the yellow colour chromogen. The formation of yellow colour and their intensity is based on the presence of GSH content in tissue sample. The changes of absorbance were noted by spectrophotometer (DU 640B Spectrophotometer, Beckman Coulter Inc., CA, USA) at 412

nm wavelength. These readings are used for the further calculation of GSH levels in tissue samples. The results were expressed as μM of GSH / mg of protein.

2.7.4. Estimation of AChE level in zebrafish brain

The AChE activity level of zebrafish brain samples were estimated by spectroscopic method as described by Ellman *et al.* [26]. Briefly, 500 μl of brain supernatant was mixed with 0.25 ml of 0.001 M of DTNB and allow developing the yellow colour chromogen products. The formation of yellow colour and their intensity is based on the ability of AChE to conversion of acetylthiocholine content. It indicates the presence of active AChE level. The change of absorbance was noted by spectrophotometrically (DU 640B Spectrophotometer, Beckman Coulter Inc., CA, USA) at 420 nm wavelength. These readings were used for the further calculation of AChE activity levels in tissue sample. The AChE activity was calculated by using the specific formula *i.e.*, $R = \delta \text{ O.D} \times \text{Volume of assay (3 ml)} / \epsilon \times \text{mg of protein}$. Hence, R is representing the rate of enzyme activity in 'n' mole of acetylthiocholine iodide hydrolyzed per minute per mg protein. O.D. is representing a change of absorbance per minute. ϵ is representing the extinction coefficient value *i.e.*, 13600 per mole per centimetre. The results were expressed as μM of acetylthiocholine hydrolysis per milligram of protein per minute.

2.7.5. Estimation of total protein level in zebrafish brain

The total protein level of zebrafish brain samples were estimated by spectroscopic method as described by Lowry *et al.* [27]. Briefly, 300 μl of zebrafish brain supernatants were diluted with distilled water upto 1 ml. Further, 5 ml of Lowry's reagent was mixed with solution and allow standing for further 15 minutes at room temperature (37 °C). Then 0.5 ml of Folin-Ciocalteu reagent was added slowly and vortexed vigorously at room temperature (37 °C) for 30 min. The clear purple chromogen was formed. The formation of purple colour and their intensity is based on the presence of protein content in tissue sample. The change of absorbance was noted by spectrophotometrically (DU 640B, UV-Spectrophotometer, Beckman Coulter Inc., CA, USA) at 750 nm wavelength. These readings were used for the further calculation of total protein levels in tissue samples. The results were expressed as mg of protein per ml of supernatant.

2.8. Statistical analysis

All the results were expressed as mean \pm standard deviation (SD). Data obtained from behavioural tests were statistically analyzed using one-way analysis of variance (ANOVA) followed by Tukey's test were applied by using Graph pad prism Version-5.0 software. The data of tissue biomarker *i.e.*, TBARS, GSH and AChE levels were analyzed using one way ANOVA followed by Tukey's multiple range tests were applied for Post-hoc analysis by using Graph pad prism Version-5.0 software. A probability value of $p < 0.05$ was considered to be

statistically significant.

3. Results

3.1. Assessment of diabetes and vascular dysfunction

The intraperitoneal injection of STZ (350 mg/kg) produces the significant ($p < 0.05$) raising of blood plasma glucose levels above 15 mM. It indicates the stabilised levels of elevated blood glucose levels leads to develop the diabetes when compared to normal control group. In addition, on 28th day the level of HcY was raised (*i.e.*, 24 $\mu\text{g/ml}$) the above the normal *i.e.*, 13 $\mu\text{g/ml}$. HcY is a primary markers of vascular dysfunction and it cause the AD and VaD [28,29]. The pre-treatment of CP (20 and 40 mg/kg; *i.p.*) shown to produce the ameliorative effect in STZ induced above biochemical changes in dose dependent manner. In addition, the pretreatment of reference control *i.e.*, insulin (100 mM) and donepezil (10 mg/kg; *i.p.*) also produce the significant attenuation of STZ induced plasma biomarker changes. It indicates that, the administration of CP possess the significant ameliorative role in the STZ associated diabetes and vascular dysfunction. The results are tabulated in **Table 1**.

Table 1: Effect of CP in STZ induced diabetic vascular dysfunction

Groups	Glucose ($\mu\text{M} / \text{L}$)	HcY ($\mu\text{M} / \text{L}$)
Normal	4.81 \pm 0.6	12.8 \pm 0.07
STZ (350)	16.9 \pm 0.4 ^a	24.7 \pm 0.004 ^a
STZ + CP (20)	10.4 \pm 0.5 ^b	6.4 \pm 0.003 ^b
STZ + CP (40)	8.12 \pm 0.9 ^b	8.6 \pm 0.007 ^b
STZ + Insulin (100 mM)	5.36 \pm 0.6 ^b	10.9 \pm 0.007 ^b
STZ + Donepezil (10)	7.24 \pm 0.7 ^b	9.5 \pm 0.009 ^b

In this table value express the effect of CP on tissue biomarker changes. Digits in parenthesis indicate dose mg/kg. Data were expressed as mean \pm SD, n = 20 zebrafish per group. ^a $p < 0.05$ Vs normal group. ^b $p < 0.05$ Vs STZ control group. Abbreviation: STZ, streptozotocin; CP, curcumin phytosome; HcY, homocysteine; and AChE, acetylcholinesterase.

3.2. Assessment of STZ induced vascular dysfunction associated dementia

The administration of STZ (350 mg/kg; *i.p.*) produce the significant ($p < 0.05$) rising of blood glucose and homocysteine levels which leads to raise the diabetes associated VaD. The VaD type of abnormal memory function was assessed by different test such as light & dark chamber test; partition preference test; three (horizontal) compartment tests; and T-maze test. The role of CP in STZ induced diabetic VaD type of cognitive impairment expressed in following section.

3.2.1. Effect of CP in light and dark chamber test

The intraperitoneal injection of STZ (350 mg/kg) produces the significant ($p < 0.05$) impairment of vascular dementia type of memory. And, it is tested in light and dark chamber test apparatus; the results are indicates the decreasing TSLC and raising NEDC values as compared to normal control group. The pretreatment of CP (20 and 40 mg/kg; *i.p.*) shown to produce the ameliorative effect in STZ induced cognitive impairment in dose dependent manner. In addition, the pretreatment of reference control *i.e.*, insulin (100 mM) and donepezil (10 mg/kg; *i.p.*) also produce the significant attenuation of STZ induced cognitive impairment changes. It indicates that, the administration of CP possess the significant role in the improvement of STZ associated VaD type of memory. The results are illustrated in **Figure 1a and 1b**.




Figure 1: Effect of CP on light and dark chamber test. Digits in parenthesis indicate dose mg/kg. Data were expressed as mean \pm SD, $n = 6$ zebrafish per group. ^a $p < 0.05$ Vs normal group. ^b $p < 0.05$ Vs STZ control group. Abbreviation: STZ, streptozotocin; TSLC, time spent in light chamber; and NEDC, number of entry to the dark chamber.

3.2.2. Effect of CP in partition preference test

The intraperitoneal injection of STZ (350 mg/kg) produces the significant ($p < 0.05$) impairment of vascular dementia type of memory. And, it is tested in partition preference test apparatus; the results are indicates the decreasing TSTC and % ETC values as compared to normal control group. The pretreatment of CP (20 and 40 mg/kg; *i.p.*) shown to produce the ameliorative effect in STZ induced cognitive impairment in dose dependent manner. In addition, the pretreatment of reference control *i.e.*, insulin (100 mM) and donepezil (10 mg/kg; *i.p.*) also produce the significant attenuation of STZ induced cognitive impairment changes. It indicates that, the administration of CP possess the significant role in the improvement of STZ associated VaD type of memory. The results are illustrated in **figure 2a and 2b**.

3.2.3. Effect of CP in three horizontal compartment test

The intraperitoneal injection of STZ (350 mg/kg) produces the significant ($p < 0.05$) impairment of vascular dementia type of memory. And, it is tested in three horizontal compartment test apparatus; the results are indicates the decreasing TSUS and increasing the TSLS values as compared to normal control group. The pretreatment of CP (20 and 40 mg/kg; *i.p.*)

shown to produce the ameliorative effect in STZ induced cognitive impairment in dose dependent manner. In addition, the pretreatment of reference control i.e., insulin (100 mM) and donepezil (10 mg/kg; *i.p.*) also produce the significant attenuation of STZ induced cognitive impairment changes. It indicates that, the administration of CP possess the significant role in the improvement of STZ associated VaD type of memory. The results are illustrated in **Figure 3a and 3b**.




Figure 2: Effect of CP on partition preference test. Digits in parenthesis indicate dose mg/kg. Data were expressed as mean \pm SD, $n = 6$ zebrafish per group. ^a $p < 0.05$ Vs normal group. ^b $p < 0.05$ Vs STZ control group. Abbreviation: STZ, streptozotocin; TSTC, time spent in target chamber; and % ETC, entry to the target chamber.




Figure 3: Effect of CP on horizontal compartment test. Digits in parenthesis indicate dose mg/kg. Data were expressed as mean \pm SD, $n = 6$ zebrafish per group. ^a $p < 0.05$ Vs normal group. ^b $p < 0.05$ Vs STZ control group. Abbreviation: STZ, streptozotocin; TSUS, time spent in upper segment; and TSLS, time spent in lower segment.

3.2.4. Effect of CP in T-maze test

The intraperitoneal injection of STZ (350 mg/kg) produces the significant ($p < 0.05$) impairment of vascular dementia type of memory. And, it is tested in T-maze test apparatus; the results are indicates the increasing TL and decreasing % TPSA values as compared to normal control group. The pretreatment of CP (20 and 40 mg/kg; *i.p.*) shown to produce the ameliorative effect in STZ induced cognitive impairment in dose dependent manner. In addition, the pretreatment of reference control insulin (100 mM) and donepezil (10 mg/kg; *i.p.*) also produce the significant attenuation of STZ induced cognitive impairment changes. It indicates that, the administration of CP possess the significant role in the improvement of STZ associated VaD type of memory. The results are illustrated in **Figure 4a and 4b**.




Figure 4: Effect of CP on T-maze test. Digits in parenthesis indicate dose mg/kg. Data were expressed as mean \pm SD, $n = 6$ zebrafish per group. ^a $p < 0.05$ Vs normal group. ^b $p < 0.05$ Vs STZ control group. Abbreviation: STZ, streptozotocin; TL, transfer latency; % TPSA, percentage target preference of short arm

3.3. Effect of CP in biomarker changes in zebrafish brain

The intraperitoneal injection of STZ (350 mg/kg) produces the significant ($p < 0.05$) raising of brain TBARS and AChE activity levels; and decrease the GSH level when compared to normal control group. The pre-treatment of CP (20 and 40 mg/kg; *i.p.*) shown to produce the ameliorative effect in STZ induced biochemical changes in dose dependent manner. In addition, the pretreatment of reference control *i.e.*, insulin (100 mM) and donepezil (10 mg/kg; *i.p.*) also produce the significant attenuation of STZ induced biomarker changes in zebrafish brain samples. It indicates that, the administration of CP possess the significant role in the improvement of STZ associated VaD type of memory via anti-oxidant, anti-inflammatory and enzymatic regulation cholinergic neurotransmission. The results are tabulated in **Table 2**.

Table 2: Effect of CP in STZ induced vascular dysfunction associated tissue biomarker changes.

Groups	GSH (μM / mg of protein)	TBARS (nM / mg of protein)	AChE (μM / mg of protein / min)
Normal	5.46 \pm 0.03	0.17 \pm 0.007	18.3 \pm 1.21
STZ (350)	2.42 \pm 0.04 ^a	0.52 \pm 0.004 ^a	43.5 \pm 1.51 ^a
STZ + CP (20)	4.83 \pm 0.06 ^b	0.29 \pm 0.003 ^b	27.2 \pm 1.09 ^b
STZ + CP (40)	4.87 \pm 0.04 ^b	0.21 \pm 0.007 ^b	24.7 \pm 0.96 ^b
STZ + Insulin (100 mM)	5.25 \pm 0.05 ^b	0.18 \pm 0.002 ^b	20.3 \pm 1.24 ^b
STZ + Donepezil (10)	5.62 \pm 0.07 ^b	0.16 \pm 0.009 ^b	19.6 \pm 1.15 ^b

In this table value express the effect of CP on tissue biomarker changes. Digits in parenthesis indicate dose mg/kg. Data were expressed as mean \pm SD, n = 20 zebrafish per group. ^a $P < 0.05$ Vs normal group. ^b $P < 0.05$ Vs STZ control group. Abbreviation: STZ, streptozotocin; CP, curcumin phytosome; GSH, reduced glutathione; TBARS, thiobarbituric acid reactive substances; and AChE, acetylcholinesterase.

4. Discussion

The present study, revealed that, CP (20 and 40 mg/kg) significantly ameliorate the STZ (350 mg/kg; *i.p.*) induced diabetes and vascular dysfunction by reducing the levels of plasma glucose and homocysteine levels. The VaD associated cognitive impairment also assessed by using various test apparatus *i.e.*, decreasing TSLC and raising NEDC values in light and dark chamber test; decreasing TSTC and % ETC values in partition chamber test; decreasing TSUS and increasing the TSLS values in three horizontal compartment test; and increasing TL and decreasing % TPSA values in T-maze test. Moreover, the STZ induced alteration of TBARS, GSH and AChE activity levels also ameliorated by CP treatment in zebrafish. The present results are supported by the readings of reference control *i.e.*, insulin and donepezil treated group.

STZ is one of potent toxic agents for β cells of Langerhans of islets leads to enhance the type-I diabetic mellitus. In addition, the chronic abnormalities of metabolic changes *i.e.*, accumulation of glucose, proteins and other metabolic waste products in the circulation induce the endothelial cell damage [30,31]. The hallmark of vascular damage is rising of plasma homocysteine. In addition, STZ potentially alter the cognitive centre of the brain *i.e.*, hippocampus via over activation of post-synaptic glutamate and N-methyl-D-aspartate (NMDA) receptors [32,33]. Paradoxically, STZ directly act on neuronal tissue leads to alter the cellular molecules as well as cytoskeletal protein which in turn cause the neurovascular damage and VaD [34]. Furthermore, the multiple neurovascular complications occurs due to STZ induced metabolic abnormalities followed by enhance the accumulation of free radical, inflammatory mediators and neurodegenerative prion proteins [35,36]. In diabetes condition, the various cellular and molecular changes of tissue leads to cause the multiple tissue damage like heart, kidney and brain including vascular system [31]. The administration of insulin is known to enhance the tissue function via multiple pharmacological mechanisms. STZ associated metabolic dysfunc-

tion reported to produce the vascular dysfunction as well as AD progression [37,38]. In addition, insulin resistance also raises the risk of AD progress via down regulation insulin receptors in brain [37]. Currently, novel insulin delivery mechanism and usage of insulin sensitizers are well documented to attenuate the AD progress [39,40]. The primary hallmark of VaD is alteration brain acetylcholinesterase activity. The inhibitor of acetylcholinesterase activity such as donepezil is widely accepted for the cognitive impairment disorders in preclinical and clinical conditions [41,42]. In the present study, donepezil is used as reference control. In addition, insulin and donepezil has own anti-oxidant, anti-inflammatory and neuroprotective actions [40, 43]. The similar pharmacological actions are observed in the present study. Curcumin has potential neuroprotective action via anti-oxidant, anti-inflammatory and anti-apoptotic actions. However, the primary drawback of this medicine in clinical setup is blood brain barrier (BBB) crossing ability. The novel techniques *i.e.*, phytosome has promising role in enhancement of bioavailability and BBB crossing ability [44,45]. In this study, CP was employed to prove the beneficial effect in STZ induced VaD. The pretreatment of CP revealed the ameliorative effect in STZ induced VaD with regulation biochemical marker changes.

The curcumin is documented to ameliorate neuronal damage and vascular complication [46,47]. In addition, it also documented to enhance the memory function against STZ associated cognitive impairment in rodent [48,49]. The established mechanism of curcumin is free radical scavenger and anti-inflammatory actions. However, beyond the anti-oxidant and anti-inflammatory actions of curcumin is also playing a key role in multiple cellular and molecular actions such as regulation of neurotransmitter, hormonal modulation, free calcium mobility, apoptosis and necrotic actions [48,50]. The cognitive improving action of CP in STZ model reveals that, it possess the endogenous anti-oxidant *i.e.*, raise the reduced glutathione action, reduction of inflammatory reactions *i.e.*, decrease the lipid peroxidation and neurotransmitter regulatory actions *i.e.*, reduction of AChE activity. Crucially, the CP is key molecule to enhancement of cognitive function against STZ toxicity. The primary outcome of this research work proves that, CP attenuate the vascular damage associated cognitive dysfunction. So it can be evaluated in clinical condition of VaD due to its solving nature of clinical problem *i.e.*, lack of bioavailability and poor BBB crossing ability. Hence, CP may be a future medicine for the treatment of neurodegenerative disorders like memory disorders due to its potential anti-diabetic, reduction of homocysteine accumulation, anti-oxidative, anti-lipidperoxidative and acetylcholine esterase inhibitory actions. However, the extensive study is required to prove the exact molecular mechanism of CP in multiple neurovascular complication with different pathophysiological conditions.

5. Funding source

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

6. Acknowledgement

The authors are thankful to the Jagdguru Sri Shivarathreeshwaara University, JSS College of Pharmacy, Mysuru -570 015, Karnataka (India) for unconditional support and providing technical facilities for this research work.

7. References

1. Chandra, S.R., et al., 'The spectrum of vascular dementia'--a retrospective study from South India. *J Assoc Physicians India*, 2014. 62(6): p. 498-503.
2. Okano, H., Stem cell biology of the central nervous system. *J Neurosci Res*, 2002. 69(6): p. 698-707.
3. Parle, M., N. Singh, and M. Vasudevan, Regular rehearsal helps in consolidation of long term memory. *J Sports Sci Med*, 2006. 5(1): p. 80-88.
4. Yu, D., et al., Hippocampal Administration of Levothyroxine Impairs Contextual Fear Memory Consolidation in Rats. *Front Cell Neurosci*, 2017. 11: p. 223.
5. Sharma, N., N. Khurana, and A. Muthuraman, Lower vertebrate and invertebrate models of Alzheimer's disease - A review. *Eur J Pharmacol*, 2017. 815: p. 312-323.
6. Van Houcke, J., et al., Successful optic nerve regeneration in the senescent zebrafish despite age-related decline of cell intrinsic and extrinsic response processes. *Neurobiol Aging*, 2017. 60: p. 1-10.
7. Kamel, M. and N. Ninov, Catching new targets in metabolic disease with a zebrafish. *Curr Opin Pharmacol*, 2017. 37: p. 41-50.
8. Palmer, T., et al., Action sequencing in the spontaneous swimming behavior of zebrafish larvae - implications for drug development. 2017. 7(1): p. 3191.
9. azza, M., et al., Primary cerebral blood flow deficiency and Alzheimer's disease: shadows and lights. *J Alzheimers Dis*, 2011. 23(3): p. 375-389.
10. Lim, S.H. and J. Lee, Protection of the brain through supplementation with larch arabinogalactan in a rat model of vascular dementia. *Nutr Res Pract*, 2017. 11(5): p. 381-387.
11. Sharma, B. and N. Singh, Attenuation of vascular dementia by sodium butyrate in streptozotocin diabetic rats. *Psychopharmacology (Berl)*, 2011. 215(4): p. 677-687.
12. Utkan, T., et al., Etanercept improves cognitive performance and increases eNOS and BDNF expression during experimental vascular dementia in streptozotocin-induced diabetes. *Curr Neurovasc Res*, 2015. 12(2): p. 135-146.
13. Farina, N., et al., Homocysteine concentrations in the cognitive progression of Alzheimer's disease. *Exp Gerontol*, 2017. 99: p. 146-150.
14. Moretti, R., et al., Vitamin D, Homocysteine, and Folate in Subcortical Vascular Dementia and Alzheimer Dementia. *Front Aging Neurosci*, 2017. 9: p. 169.
15. Intine, R.V., A.S. Olsen, and M.P. Sarras, Jr., A zebrafish model of diabetes mellitus and metabolic memory. *J Vis Exp*, 2013(72): p. e50232.
16. Kinkel, M.D., et al., Intraperitoneal injection into adult zebrafish. *J Vis Exp*, 2010(42).
17. Dubey, S., et al., Protective effect of rutin on impairment of cognitive functions of due to antiepileptic drugs on zebrafish model. *Indian journal of pharmacology*, 2015. 47(1): p. 86.

18. Buccafusco, J.J., *Methods of behavior analysis in neuroscience*. 2009: Crc Press.
19. Colwill, R.M., et al., Visual discrimination learning in zebrafish (*Danio rerio*). *Behav Processes*, 2005. 70(1): p. 19-31.
20. Pedroso, G.L., et al., Blood collection for biochemical analysis in adult zebrafish. *J Vis Exp*, 2012(63): p. e3865.
21. Babaei, F., et al., Novel blood collection method allows plasma proteome analysis from single zebrafish. *J Proteome Res*, 2013. 12(4): p. 1580-1590.
22. Ambade, V.N., Y.V. Sharma, and B.L. Somani, METHODS FOR ESTIMATION OF BLOOD GLUCOSE : A COMPARATIVE EVALUATION. *Med J Armed Forces India*, 1998. 54(2): p. 131-133.
23. Radha Rama Devi, A., S.M. Naushad, and K.C. Prasad, Evaluation of total plasma homocysteine in Indian newborns using heel-prick samples. *Indian J Pediatr*, 2006. 73(6): p. 503-508.
24. Ohkawa, H., N. Ohishi, and K. Yagi, Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. *Anal Biochem*, 1979. 95(2): p. 351-358.
25. Ellman, G.L., Tissue sulfhydryl groups. *Arch Biochem Biophys*, 1959. 82(1): p. 70-77.
26. Ellman, G.L., et al., A new and rapid colorimetric determination of acetylcholinesterase activity. *Biochem Pharmacol*, 1961. 7: p. 88-95.
27. Lowry, O.H., et al., Protein measurement with the Folin phenol reagent. *J Biol Chem*, 1951. 193(1): p. 265-275.
28. Lee, S.J., et al., Homocysteine-induced peripheral microcirculation dysfunction in zebrafish and its attenuation by L-arginine. *Oncotarget*, 2017. 8(35): p. 58264-58271.
29. Singh, M. and A. Prakash, Possible role of endothelin receptor against hyperhomocysteinemia and beta-amyloid induced AD type of vascular dementia in rats. *Brain Res Bull*, 2017. 133: p. 31-41.
30. Kang, E.B. and J.Y. Cho, Effects of treadmill exercise on brain insulin signaling and β -amyloid in intracerebroventricular streptozotocin induced-memory impairment in rats. *J Exerc Nutrition Biochem*, 2014. 18(1): p. 89-96.
31. Lopez-Diez, R., et al., Ager deletion enhances ischemic muscle inflammation, angiogenesis, and blood flow recovery in diabetic mice. *Arterioscler Thromb Vasc Biol*, 2017. 37(8): p. 1536-1547.
32. Gardoni, F., et al., Effects of streptozotocin-diabetes on the hippocampal NMDA receptor complex in rats. *J Neurochem*, 2002. 80(3): p. 438-447.
33. Motawi, T.K., et al., Coenzyme Q10 and niacin mitigate streptozotocin - induced diabetic encephalopathy in a rat model. *Metab Brain Dis*, 2017. 32(5): p. 1519-1527.
34. Murtishaw, A.S., et al., Effect of acute lipopolysaccharide-induced inflammation in intracerebroventricular-streptozotocin injected rats. *Neuropharmacology*, 2016. 101: p. 110-122.
35. Blaes, F., Diagnosis and therapeutic options for peripheral vasculitic neuropathy. *Ther Adv Musculoskelet Dis*, 2015. 7(2): p. 45-55.
36. Collins, M.P. and R.D. Hadden, The nonsystemic vasculitic neuropathies. *Nat Rev Neurol*, 2017. 13(5): p. 302-316.
37. Salkovic-Petrisic, M. and S. Hoyer, Central insulin resistance as a trigger for sporadic Alzheimer-like pathology: an experimental approach. *J Neural Transm Suppl*, 2007(72): p. 217-233.
38. Ramos-Rodriguez, J.J., et al., Differential central pathology and cognitive impairment in pre-diabetic and diabetic mice. *Psychoneuroendocrinology*, 2013. 38(11): p. 2462-2475.

39. Sebastiao, I., et al., Insulin as a bridge between type 2 diabetes and Alzheimer disease - how anti-diabetics could be a solution for dementia. *Front Endocrinol (Lausanne)*, 2014. 5: p. 110.
40. Ye, F., et al., Impact of insulin sensitizers on the incidence of dementia: A Meta-Analysis. *Dement Geriatr Cogn Disord*, 2016. 41(5-6): p. 251-260.
41. Zaninotto, A.L., et al., Acute cognitive effects of donepezil in young, healthy volunteers. *Hum Psychopharmacol*, 2009. 24(6): p. 453-464.
42. Chaudhari, K.S., et al., Neurocognitive effect of nootropic drug brahmi (*Bacopa monnieri*) in Alzheimer's disease. *Ann Neurosci*, 2017. 24(2): p. 111-122.
43. Dias, K.S., et al., Design, synthesis and evaluation of novel feruloyl-donepezil hybrids as potential multitarget drugs for the treatment of Alzheimer's disease. *Eur J Med Chem*, 2017. 130: p. 440-457.
44. Kesarwani, K., R. Gupta, and A. Mukerjee, Bioavailability enhancers of herbal origin: An overview. *Asian Pac J Trop Biomed*, 2013. 3(4): p. 253-266.
45. Jager, R., et al., Comparative absorption of curcumin formulations. *Nutr J*, 2014. 13: p. 11.
46. Kant, V., et al., Combined effect of substance P and curcumin on cutaneous wound healing in diabetic rats. *J Surg Res*, 2017. 212: p. 130-145.
47. Karuppagounder, V., et al., Tiny molecule, big power: Multi-target approach for curcumin in diabetic cardiomyopathy. *Nutrition*, 2017. 34: p. 47-54.
48. Samy, D.M., et al., Downstream modulation of extrinsic apoptotic pathway in streptozotocin-induced Alzheimer's dementia in rats: Erythropoietin versus curcumin. *Eur J Pharmacol*, 2016. 770: p. 52-60.
49. Bassani, T.B., et al., Effects of curcumin on short-term spatial and recognition memory, adult neurogenesis and neuroinflammation in a streptozotocin-induced rat model of dementia of Alzheimer's type. *Behav Brain Res*, 2017. 335: p. 41-54.
50. Oz, A. and O. Celik, Curcumin inhibits oxidative stress-induced TRPM2 channel activation, calcium ion entry and apoptosis values in SH-SY5Y neuroblastoma cells: Involvement of transfection procedure. *Mol Membr Biol*, 2016. 33(3-5): p. 76-88.